Menu Back to CMC-Workshop

Overview

CMC systems and processes play a pivotal role in the development, licensure, manufacture, and ongoing marketing of biopharmaceutical and device products that are consistently effective, safe, and high quality for patients.

DIA's CMC Workshop will provide a thorough understanding of the regulatory, technical, and quality requirements and strategies needed to support problem-solving as well as continuous improvements and innovation in biopharmaceutical manufacturing. Opportunities for interactive sharing of information and approaches will be an important part of the program.

This program has been developed in collaboration with the DIA CMC Working Group and Regulatory Affairs Community.


Previous attendees have said:

"The event was a great combination of high-quality science, current and emerging trends in the global regulatory environment, and outstanding networking opportunities with senior pharma and agency leaders."

"It was a great event, very relevant topics but also a great opportunity to network."


Content Preview Webinar

Compliance and Change Control: Checking that the Manufacture/CMC is Maintained in Accord with the Terms of the License
March 13 | 10:00-11:00AM ET
This webinar will take on the complex problem of managing global post-approval CMC changes.
Register today.

Who should attend?

Professionals involved in:

  • CMC Regulatory Affairs
  • CMC Writing
  • Quality Assurance/Quality Control
  • Regulatory Compliance
  • API Development and Manufacturing
  • Formulation Development and Manufacturing
  • Analytical Development
  • CMC Lifecycle Management
  • CMC Project Management

Program Committee

  • LeeAnn L Chambers, MS
    LeeAnn L Chambers, MS Principal Research Scientist, Global Regulatory Affairs, CMC - Devices
    Eli Lilly and Company, United States
  • Andrew  Chang, PhD
    Andrew Chang, PhD Vice President, Quality and Regulatory Compliance, QI&I, Corporate Quality
    Novo Nordisk A/S, United States
  • Cheryl  Emery
    Cheryl Emery Associate VP, GRACS and Global Head CMC Pre-Approval Pharmaceuticals
    Merck Research Laboratories, United States
  • M. Scott  Furness, PhD
    M. Scott Furness, PhD Deputy Director, ONDP, OPQ, CDER
    FDA, United States
  • Annie W Sturgess, PhD
    Annie W Sturgess, PhD Vice President, Global Regulatory Sciences, CMC
    Bristol-Myers Squibb Company, United States
Load More

Contact us

Registration Questions?

Send Email
1.888.257.6457


Digital Learning Catalog

DIA Learning: eLearning Soultions
Download